摘要
目的探讨肺癌患者外周血中CD4^＋CD25^HiCD127^Lo调节性T细胞（Treg）占CD4^＋淋巴细胞比例的变化及其意义。方法采用流式细胞术检测肺癌患者30例（鳞癌20例、腺癌10例）及健康人（对照组）20名外周血中Treg的变化；ELISA法检测同一标本血清中自细胞介素10（IL-10），转化生长因子-β（TGF—β）的表达水平。结果鳞癌、腺癌患者外周血中Treg占CD4^＋T淋巴细胞的比例分别为（6．81±1．52）％、（7．08±1．17）％，两组间比较差异无统计学意义（P〉0．05），二者均高于对照组的（4．91±1．24）％，差异有统计学意义（P〈0．05）；肺癌组血清中IL—10水平为（24．36±4．02）ng／ml，高于健康对照组的（21．53±4．30）ng／ml；肺癌组血清中TGF—β水平为（218．49±35．23）ng／ml，高于健康对照组的（124．31±20．32）ng／ml。结论肺癌患者外周血中Treg比例明显升高，可能是导致免疫抑制的原因之一，并且可能通过分泌IL-10和TGF—β,发挥免疫抑制的效应。
Objective To evaluate the changes and clinical significance of CD4^＋CD25^HiCD127^Lo regulatory T cell（Treg） in peripheral blood of patients with lung cancer. Methods 30 patients with lung cancer and 20 healthy volunteers were included in this study. The proportion of Treg population in CD4^＋ T cells stained with three colors was analysed by flow cytometry. The serum level of IL-10 and TGF-β were measured by ELISA. Results The proportion of Treg in patients with squamous cell carcinoma（n =20）, adenocarcinoma （n=10） were all significantly higher than that of healthy controls （P 〈0.05）, but there was not obvious difference between the two groups with different pathological types（P 〉0.05）. Increased serum level of IL-10 and TGF-β was also detected in lung cancer patients. Conclusion The proportion of Treg is increased in lung cancer patients, which may result in the inhibition of host anti-cancer immune response by excreting IL-10 and TGF-β.
出处
《肿瘤研究与临床》
CAS
2009年第7期453-454,457,共3页
Cancer Research and Clinic
